| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Rallybio Corporation$15.73
-0.1 (-0.63%)
D 21Pipeline Score Richly Valued Biotech · Clinical
Market Cap
84.13 M
EPS
-1.45
P/E Ratio
-
Value Trade
871.90 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
212.00 K
R&D Expenses
2.87 M
Operating CF
-7.98 M
Total Assets
54.47 M
Total Liabilities
4.20 M
Equity
50.28 M
D/E Ratio
12,345
12.15 %
Week
91.56 %
1 Month
230.83 %
3 Month
225.41 %
6 Month
-86.7 %
5 Year
-86.7 %
All Time
Cash Data
Cash Position
46.80 M
Monthly Burn
2.66 M
Runway
15.9 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
27.27 K
52 Week Range
2.16 - 16
% held by Insiders
26.68 %
% held by Institutions
78.39 %
Enterprise Value
37.49 M
Total Shares
5.30 M
Short %
20.74 %
Float Shares
1.97 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rallybio Corporation
152Total events
0Upcoming
39Tier-1 (high impact)
2021 – 2026Coverage
Event history 152
Q2 2026
◆Trial InitiationRLYB116Trial
Initiation of Phase 2 proof of concept study in immune PTR
immune platelet transfusion refractoriness (PTR)source ↗
Feb 17, 2026
▲Full ResultsRLYB116Clinical Data
Positive Phase 1 results for RLYB116 demonstrating complete and sustained complement inhibition
complement-mediated diseasessource ↗
2026
◆Trial InitiationcizutamigTrial
Global Phase 2 study initiation for cizutamig in ILD
interstitial lung disease secondary to rheumatological diseasessource ↗
2026
◆Trial InitiationREV102Trial
REV102 Phase 1 study expected to initiate in 2026
hypophosphatasia (HPP)source ↗
Q4 2025
◆Topline ReadoutRLYB116Clinical Data
RLYB116 confirmatory PK PD study data expected
immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS)source ↗
Drug Pipeline Intelligence
D21
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 19%
Micro Cap (rank 739 of 911)
Percentile RankRallybio Corporation faces pipeline headwinds (21/100), with $188M risk-adjusted pipeline value, led by RLYB116 in Hematologic Diseases (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RLYB116 Small molecule | Hematologic Diseases | Phase 1 | NCT06797375 | 10% | $188M | COMPLETED | 16 | - | - | Feb 23, 2026 | - | Feb 27, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
RLYB116 | complement-mediated diseases | Phase 1 | 2026-02-17 | complete and sustained inhibition of terminal complement at a 300 mg dose Read More | Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement Read More | |
RLYB116 | complement-mediated diseases | Phase 1 | 2026-02-17 | complete and sustained inhibition of terminal complement at a 300 mg dose Read More | Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement Read More | |
RLYB116 | complement-mediated diseases | Phase 1 | 2026-02-17 | complete and sustained inhibition of terminal complement at a 300 mg dose Read More | Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RLYB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RLYB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RLYB▲ +16.7%on this news
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Rallybio Corporation and Avenzo Therapeutics have announced a merger agreement aimed at advancing next-generation oncology therapies. The deal includes a substantial $215 million private placement to support their initiatives. This collaboration is expected to enhance their capabilities in developing innovative cancer treatments.
Read more →RLYB▲ +45.5%on this news
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Rallybio Corporation has announced a merger agreement with Candid Therapeutics, aiming to create a leading company in T-cell engager therapeutics for autoimmune diseases. The merger, expected to close in mid-2026, includes a significant financing round of over $505 million. The combined entity will operate under the name Candid Therapeutics, Inc. and focus on advancing multiple clinical programs.
Read more →RLYB▼ -10.2%on this news
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Rallybio Corporation announced positive results from its Phase 1 study of RLYB116, a C5 inhibitor targeting complement-mediated diseases. The trial showed complete and sustained inhibition of terminal complement at a 300 mg dose with a favorable safety profile. The company plans to initiate a Phase 2 study in immune platelet transfusion refractoriness in the second half of 2026.
Read more →RLYBRallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates - RLYB116 Confirmatory PK PD Study Data Expected in 4Q 2025 - - Generated $20 Million from Sale of Interest in REV102 - - Cash Runway Ex
Rallybio Corporation has reported its financial results for the third quarter of 2025, showcasing a net income of $16 million, a turnaround from a loss the previous year. The company generated $20 million from the sale of interest in REV102 and has extended its cash runway through 2027. Progress on its lead program, RLYB116, is notable as it moves to the second cohort in its Phase 1 clinical trials, with results anticipated in Q4 2025. However, a slight decrease in revenue suggests ongoing challenges in market performance.
Read more →RLYBRallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK PD Study on Track for 3Q and 4Q 2025, Respectively - - Sold Inter
Rallybio Corporation announced its second quarter 2025 financial results, reporting a net loss of $9.7 million. The company is on track for data readouts from both cohorts of its RLYB116 confirmatory PK PD study in Q3 and Q4 2025, reflecting progress in its lead program. Additionally, Rallybio strengthened its financial position through the sale of its interest in REV102 for up to $25 million, extending its cash runway into mid-2027. The company continues to focus on developing therapies for rare diseases while managing its portfolio strategically.
Read more →RLYBRallybio Reports First Quarter 2025 Financial Results and Provides Business Updates - On Track to Initiate Dosing in RLYB116 Confirmatory PK PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 - - $54
Rallybio Corporation has reported first quarter 2025 financial results, highlighting progress toward initiating dosing in a confirmatory pharmacokinetic pharmacodynamic study for its lead product RLYB116 in 2Q 2025. The company currently holds $54.5 million in cash, projecting operational support into the first half of 2027. Noteworthy upcoming data readouts are expected for both RLYB116 and REV102 in late 2025. However, Rallybio has faced setbacks, including the discontinuation of the RLYB212 program due to inadequate efficacy data and a significant workforce reduction.
Read more →RLYB▼ -41.2%on this news
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT -- RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy -- -- RLYB116 Confi
Rallybio Corporation has announced the discontinuation of its RLYB212 program aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). This decision follows Phase 2 clinical trial results that revealed the drug's failure to achieve necessary pharmacokinetic target concentrations, including the minimum required for efficacy. Despite this setback, Rallybio plans to focus on the development of RLYB116 and other emerging programs, aiming to innovate within the realm of rare diseases. They intend to initiate confirmatory studies for RLYB116 in mid-2025.
Read more →RLYBRallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 - Initiatio
Rallybio Corporation reported its financial results for Q4 and the full year of 2024, showing a net loss but strong cash reserves. The company is advancing several clinical trials, including the RLYB212 Phase 2 trial, which aims to provide key safety and pharmacokinetic data in 2025. Rallybio also plans to initiate a confirmatory study for its C5 inhibitor, RLYB116, while its ENPP1 inhibitor, REV102, is moving toward a Phase 1 study in 2026. The financial results indicate improved operational discipline, yet the company still faces significant losses.
Read more →RLYBRallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates CTA Approvals Received for RLYB212 Phase 2 Clinical Trial On Track to Initiate Screening in 4Q 2024 $75.1 Million in Cash, Cash Equivale
Rallybio Corporation reported its third quarter 2024 financial results, highlighting significant developments including the approval of clinical trial applications for its RLYB212 Phase 2 trial. The company has $75.1 million in cash and equivalents, affording a financial runway into mid-2026. Progress in the RLYB116 program is promising, with important data expected to be shared in December. Despite a reported net loss of $11.5 million, the company shows improved financial management compared to the previous year.
Read more →RLYBRallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 $88.6 Million in Cash
Rallybio Corporation announced its second quarter financial results for 2024, reporting a net loss of $16.2 million. The company is on track to initiate a Phase 2 trial for its lead candidate RLYB212 in pregnant women at higher risk of fetal and neonatal alloimmune thrombocytopenia by Q4 2024. Recent data suggests a significant underestimation of the number of pregnancies at risk of this condition, representing a considerable market opportunity. Rallybio also reported having $88.6 million in cash reserves, which is expected to fund operations into mid-2026.
Read more →RLYBRallybio Reports First Quarter 2024 Financial Results and Provides Business Updates On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 $94.2 Million in Cash,
Rallybio Corporation reported its first quarter financial results for 2024, showcasing a strong cash position of $94.2 million and plans to initiate a Phase 2 trial for RLYB212 in pregnant women at risk of FNAIT. Significant developments include a collaboration with Johnson & Johnson aimed at addressing FNAIT, and the company is conducting a natural history study to better understand FNAIT risk in diverse populations. Despite a reported net loss of $19 million, Rallybio remains focused on its key clinical-stage assets.
Read more →RLYBRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) Rallybio to Receive Funding for FNAIT Awareness Initiative and
Rallybio Corporation has announced a collaboration with Johnson Johnson to develop therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The partnership includes an equity investment of $6.6 million and aims to raise awareness about FNAIT while advancing the clinical development of Rallybio's investigational therapy, RLYB212. This therapy is designed to prevent alloimmunization in pregnant people, with a Phase 2 study expected to begin in the second half of 2024. Currently, there are no approved treatments for FNAIT, highlighting the significance of this collaborative effort.
Read more →RLYB▼ -8.7%on this news
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results -- Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212 Company to Proceed Forward with Clinical Trial
Rallybio has reported its fourth quarter and full year 2023 financial results, highlighting significant advancements in its clinical programs, particularly for RLYB212. The company received favorable feedback from the European Medicines Agency, allowing it to progress with a Phase 2 clinical trial set to begin in the second half of 2024. Despite announcing a substantial workforce cut to reinvigorate focus on its primary assets and manage operational costs, Rallybio maintains a strong financial position with $109.9 million in cash reserves projected to extend operations through mid-2026.
Read more →RLYB▲ +24%on this news· ran to +42% by day 3
Rallybio Announces Portfolio Prioritization and Provides Corporate Update Prioritization of Phase 2-ready clinical-stage programs RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patie
Rallybio Corporation is prioritizing its portfolio of clinical-stage programs, focusing on RLYB212 and RLYB116, which aim to address serious medical needs. The company announced a significant workforce reduction of 45% to extend its cash runway into mid-2026 while streamlining operations. They plan to initiate Phase 2 trials for RLYB212 in at-risk pregnant women by the second half of 2024. Rallybio is also optimistic about advancements in the manufacturing process of RLYB116, which could enhance treatment options for patients with complement-mediated diseases.
Read more →RLYB▼ -5.5%on this news
Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 -- 100 mg Results Demonstrated a Mean Reduction of Greater than 9
Rallybio Corporation announced preliminary results from its Phase 1 study of RLYB116, an innovative subcutaneously injected inhibitor of complement component 5. The study demonstrated a significant 93% reduction in free C5 levels with a 100 mg weekly dose, indicating potential efficacy for treating generalized myasthenia gravis and other complement-mediated diseases. While the treatment showed good tolerability, there were mild adverse events, including injection site reactions. The company has extended its cash runway to support further development, focusing on manufacturing enhancements before proceeding to Phase 2 trials.
Read more →RLYBRallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates -- RLYB212 Phase 1 Multiple Dose Cohort Complete and on Track for 4Q 2023 Data Release -- -- Initial Data from RLYB116 Phase 1 Multiple
Rallybio Corporation has reported its third quarter financial results, highlighting that the Phase 1 multiple dose cohort for RLYB212 has been completed and is on track for data release in Q4 2023. The company also anticipates preliminary data from the RLYB116 Phase 1 study to be disclosed by the end of the year. With $121.4 million in cash reserves, Rallybio is financially positioned to continue its research and developments through early 2025. However, the net loss of $18.4 million during the quarter raises concerns among investors regarding financial stability.
Read more →RLYBRallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates -- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31 st Congress of the International Society of Thrombosis and Haemo
Rallybio Corporation (NASDAQ: RLYB) reported its second quarter 2023 financial results and significant updates on its clinical programs. The results of the Phase 1b proof-of-concept study for RLYB212 highlighted a 90% reduction in platelet elimination half-life, supporting its potential therapeutic use. The Company also plans to complete the toxicology program for RLYB212 and report results from a multiple dose cohort study in Q4 2023. Rallybio's financial position remains solid with $137.8 million in cash, providing a runway into 2025.
Read more →RLYB▼ -5.6%on this news
Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective
Rallybio Corporation has announced a leadership transition with Stephen Uden, M.D., being appointed as Chief Executive Officer effective August 1, 2023. Uden, who has been with the company since its inception, will also continue his role as President and join the Board of Directors, succeeding Martin Mackay, Ph.D., who will take on the position of Executive Chairman. This transition comes as Rallybio looks to enhance its focus on developing therapies for rare diseases, with several clinical programs expected to report results in the near future.
Read more →RLYB▼ -7%on this news
Rallybio Reports First Quarter 2023 Financial Results -- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31 st Congress of the International Society of Thrombosis and Haemostasis (ISTH) in June 2023 --
Rallybio Corporation reported its first quarter financial results, highlighting progress on its clinical programs, particularly RLYB212 for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company plans to present Phase 1b proof-of-concept study results at the International Society on Thrombosis and Haemostasis Congress set for June 2023. As of March 31, 2023, Rallybio holds $150.4 million in cash, securing its operations into early 2025. Despite a net loss of $17.3 million this quarter, the company remains focused on developing therapies for rare diseases with unmet needs.
Read more →RLYB▲ +10.3%on this news· ran to -31% by day 3
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results -- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects &#x
Rallybio Corporation announced its fourth-quarter and full-year financial results, highlighting the proof-of-concept achievement for RLYB212, which effectively eliminated transfused HPA-1a positive platelets in HPA-1a negative subjects. The company reports a solid financial position with $169 million in cash, allowing operational continuity into 2025. Additionally, Rallybio is progressing with several clinical studies, including RLYB116 and ongoing collaborations to target rare diseases. The company anticipates sharing more data in the coming quarters, signaling a promising outlook for its development pipeline.
Read more →RLYBRallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
Rallybio Corporation has appointed Jonathan I. Lieber as its new Chief Financial Officer, effective February 1, 2023. Lieber succeeds Jeffrey Fryer, who is leaving the company after a transition period. With over 30 years of experience in finance and leadership roles in life sciences, Lieber is expected to contribute significantly to Rallybio's mission of developing therapies for rare diseases. The CEO expressed optimism about Lieber's contributions as the company advances its pipeline.
Read more →RLYBRallybio Reports Third Quarter 2022 Financial Results -- Preliminary results from Phase 1b study of RLYB212 showed rapid and complete elimination of transfused platelets in all subjects to date; Proof-of-concept data exp
Rallybio Reports Third Quarter 2022 Financial Results -- Preliminary results from Phase 1b study of RLYB212 showed rapid and complete elimination of transfused platelets in all subjects to date; Proof-of-concept data expected in 1Q 2023 -- -- Positive 100 mg results of Phase 1
Read more →RLYBRallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia -- Preliminary data from the ongoing Phase 1b study sho
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia -- Preliminary data from the ongoing Phase 1b study shows RLYB212 rapidly and completely eliminates transfused HPA
Read more →RLYB▼ -5.8%on this news
Rallybio Reports Second Quarter 2022 Financial Results -- Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets -- -- Phase 1 study of RLYB116 ongoing;
Rallybio Reports Second Quarter 2022 Financial Results -- Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets -- -- Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for t
Read more →RLYBRallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors NEW HAVEN, Conn. August 2, 2022-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for pat
Read more →RLYBRallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer --Company initiates an external search for its next Chief Financial Officer
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer --Company initiates an external search for its next Chief Financial Officer-- NEW HAVEN, Conn., June 2, 2022 Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to ide
Read more →RLYB▲ +6.1%on this news
Rallybio Reports First Quarter 2022 Financial Results -- Initiated Phase 1b proof-of-concept study for RLYB212 for the prevention of FNAIT; initial data expected in 3Q 2022 -- -- Phase 1 study of RLYB116 ongoing; initial
Rallybio Reports First Quarter 2022 Financial Results -- Initiated Phase 1b proof-of-concept study for RLYB212 for the prevention of FNAIT; initial data expected in 3Q 2022 -- -- Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected in 2H 2022 -
Read more →RLYB▲ +7%on this news
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors -Tim Shannon, M.D. to resign from Rallybio's Board of Directors effective at 2022 Annual Meeting of Shareholders
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors -Tim Shannon, M.D. to resign from Rallybio's Board of Directors effective at 2022 Annual Meeting of Shareholders- NEW HAVEN, Conn. April 4, 2022-- Rallybio Corporation (Nasdaq: RLYB), a clinical-s
Read more →RLYB▼ -10.6%on this news
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results -- Phase 1b proof-of-concept study for RLYB212 in development for the prevention of FNAIT on track to commence in 2Q 2022; initial data expected in 3Q
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results -- Phase 1b proof-of-concept study for RLYB212 in development for the prevention of FNAIT on track to commence in 2Q 2022; initial data expected in 3Q 2022 -- -- First healthy volunteers dosed in Phase 1 study
Read more →RLYBMARCH 2022 TAKING A DEVASTATING DISEASE – AND DEVASTATING IT. We're going there. Corporate Presentation Forward-Looking Statements–This presentation contains forward-looking statements that are based on man
MARCH 2022 TAKING A DEVASTATING DISEASE AND DEVASTATING IT. We're going there. Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to
Read more →RLYB▲ +5.1%on this news· ran to -27% by day 3
Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights -- Initiated FNAIT natural history study to inform frequency of FNAIT risk in broad population and support future potential
Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights -- Initiated FNAIT natural history study to inform frequency of FNAIT risk in broad population and support future potential registration trial -- -- On-track to announce in 4Q 2021
Read more →RLYBRallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights ̶ Completed initial public offering for $92.7 million of gross proceeds ̶ ̶ Clinical proof-of-concept da
Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights Completed initial public offering for $92.7 million of gross proceeds Clinical proof-of-concept data for RLYB211 for the prevention of FNAIT was presented at the ISTH Virtual Congr
Read more →Competitive Position
How RLYB ranks across every disease it competes inCompetitive Position is a premium feature
See how RLYB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial